DE69619233T2 - Prrs-(porcine reproductive and respiratory syndrome)-virusvakzin - Google Patents

Prrs-(porcine reproductive and respiratory syndrome)-virusvakzin

Info

Publication number: DE69619233T2
Authority: DE; Germany
Prior art keywords: virus; group; prrs; pigs; culture
Prior art date: 1995-05-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Revoked

Application number

DE69619233T

Other languages

German (de)

English (en)

Other versions

DE69619233D1 (en

Inventor

W Chladek

E Corcyca

L Harris

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Animal Health USA Inc

Original Assignee

Boehringer Ingelheim Vetmedica Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-15

Filing date

1996-05-14

Publication date

2002-08-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23750027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69619233(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-05-14 Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc

2002-03-21 Application granted granted Critical

2002-03-21 Publication of DE69619233D1 publication Critical patent/DE69619233D1/de

2002-08-22 Publication of DE69619233T2 publication Critical patent/DE69619233T2/de

2016-05-15 Anticipated expiration legal-status Critical

Status Revoked legal-status Critical Current

Links

241000700605 Viruses Species 0.000 title claims abstract description 143
208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 title claims abstract description 99
229960005486 vaccine Drugs 0.000 title claims abstract description 83
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
238000000034 method Methods 0.000 claims abstract description 19
238000002360 preparation method Methods 0.000 claims abstract description 6
241000282887 Suidae Species 0.000 claims description 113
210000004027 cell Anatomy 0.000 claims description 42
238000004519 manufacturing process Methods 0.000 claims description 19
238000003306 harvesting Methods 0.000 claims description 12
241000124008 Mammalia Species 0.000 claims description 9
230000001717 pathogenic effect Effects 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 8
239000003381 stabilizer Substances 0.000 claims description 8
241000282693 Cercopithecidae Species 0.000 claims description 7
230000028993 immune response Effects 0.000 claims description 7
210000003292 kidney cell Anatomy 0.000 claims description 7
238000004113 cell culture Methods 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
229920000159 gelatin Polymers 0.000 claims description 4
239000008273 gelatin Substances 0.000 claims description 4
230000001939 inductive effect Effects 0.000 claims description 4
238000004108 freeze drying Methods 0.000 claims description 3
238000007710 freezing Methods 0.000 claims description 2
230000008014 freezing Effects 0.000 claims description 2
230000003053 immunization Effects 0.000 claims description 2
239000012520 frozen sample Substances 0.000 claims 1
238000002649 immunization Methods 0.000 claims 1
241000282898 Sus scrofa Species 0.000 abstract description 23
201000010099 disease Diseases 0.000 abstract description 18
230000003612 virological effect Effects 0.000 abstract description 9
238000000338 in vitro Methods 0.000 abstract 1
238000002255 vaccination Methods 0.000 description 39
238000011282 treatment Methods 0.000 description 31
238000012360 testing method Methods 0.000 description 28
210000004072 lung Anatomy 0.000 description 24
230000007423 decrease Effects 0.000 description 17
239000002054 inoculum Substances 0.000 description 17
210000001519 tissue Anatomy 0.000 description 17
241001465754 Metazoa Species 0.000 description 15
206010058874 Viraemia Diseases 0.000 description 15
244000144980 herd Species 0.000 description 15
230000003902 lesion Effects 0.000 description 15
230000000241 respiratory effect Effects 0.000 description 15
210000000265 leukocyte Anatomy 0.000 description 14
238000002955 isolation Methods 0.000 description 12
201000002364 leukopenia Diseases 0.000 description 12
231100001022 leukopenia Toxicity 0.000 description 12
239000002609 medium Substances 0.000 description 12
230000000694 effects Effects 0.000 description 11
239000001963 growth medium Substances 0.000 description 11
241000710788 Lelystad virus Species 0.000 description 9
230000036039 immunity Effects 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
208000021017 Weight Gain Diseases 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000001850 reproductive effect Effects 0.000 description 8
235000019786 weight gain Nutrition 0.000 description 8
230000004584 weight gain Effects 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
230000008901 benefit Effects 0.000 description 7
238000004820 blood count Methods 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
230000002238 attenuated effect Effects 0.000 description 6
239000012894 fetal calf serum Substances 0.000 description 6
239000010410 layer Substances 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
238000003556 assay Methods 0.000 description 5
235000021053 average weight gain Nutrition 0.000 description 5
230000005540 biological transmission Effects 0.000 description 5
230000002550 fecal effect Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
230000003472 neutralizing effect Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
206010037660 Pyrexia Diseases 0.000 description 4
230000036760 body temperature Effects 0.000 description 4
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
230000008859 change Effects 0.000 description 4
210000003608 fece Anatomy 0.000 description 4
230000005847 immunogenicity Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
239000007758 minimum essential medium Substances 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
230000000405 serological effect Effects 0.000 description 4
210000002845 virion Anatomy 0.000 description 4
206010067484 Adverse reaction Diseases 0.000 description 3
238000000692 Student's t-test Methods 0.000 description 3
230000006838 adverse reaction Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
241001493065 dsRNA viruses Species 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
208000023504 respiratory system disease Diseases 0.000 description 3
238000012353 t test Methods 0.000 description 3
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
241000867607 Chlorocebus sabaeus Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241000710803 Equine arteritis virus Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010038687 Respiratory distress Diseases 0.000 description 2
241000710924 Togaviridae Species 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
206010003230 arteritis Diseases 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000002845 discoloration Methods 0.000 description 2
244000309457 enveloped RNA virus Species 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
230000003067 hemagglutinative effect Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
238000009021 pre-vaccination Methods 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
230000005801 respiratory difficulty Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
208000012153 swine disease Diseases 0.000 description 2
AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
208000035404 Autolysis Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
206010022095 Injection Site reaction Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000005107 Premature Birth Diseases 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
241000712907 Retroviridae Species 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
230000001539 anorectic effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
235000021052 average daily weight gain Nutrition 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000032625 disorder of ear Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000036541 health Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000036244 malformation Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
230000008689 nuclear function Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000028043 self proteolysis Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
208000002254 stillbirth Diseases 0.000 description 1
231100000537 stillbirth Toxicity 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229940071127 thioglycolate Drugs 0.000 description 1
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
230000007704 transition Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
230000001018 virulence Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10051—Methods of production or purification of viral material
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/815—Viral vaccine for porcine species, e.g. swine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Zoology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

DE69619233T 1995-05-15 1996-05-14 Prrs-(porcine reproductive and respiratory syndrome)-virusvakzin Revoked DE69619233T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/440,750 US6042830A (en)	1992-08-05	1995-05-15	Viral agent associated with mystery swine disease
PCT/US1996/006800 WO1996036356A1 (fr)	1995-05-15	1996-05-14	Agent viral associe a une pathologie porcine nouvelle

Publications (2)

Publication Number	Publication Date
DE69619233D1 DE69619233D1 (en)	2002-03-21
DE69619233T2 true DE69619233T2 (de)	2002-08-22

Family

ID=23750027

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69619233T Revoked DE69619233T2 (de)	1995-05-15	1996-05-14	Prrs-(porcine reproductive and respiratory syndrome)-virusvakzin

Country Status (21)

Country	Link
US (2)	US6042830A (fr)
EP (1)	EP0830142B1 (fr)
JP (1)	JP4300252B2 (fr)
KR (1)	KR19990014840A (fr)
CN (1)	CN1130227C (fr)
AT (1)	ATE213166T1 (fr)
AU (1)	AU717395B2 (fr)
BR (1)	BR9608535B1 (fr)
CA (1)	CA2221242C (fr)
CZ (1)	CZ296208B6 (fr)
DE (1)	DE69619233T2 (fr)
DK (1)	DK0830142T3 (fr)
ES (1)	ES2170234T3 (fr)
HU (1)	HU223763B1 (fr)
MX (1)	MX9708804A (fr)
PL (1)	PL184973B1 (fr)
PT (1)	PT830142E (fr)
RU (1)	RU2166327C2 (fr)
SK (1)	SK283579B6 (fr)
UA (1)	UA39991C2 (fr)
WO (1)	WO1996036356A1 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0587780B2 (fr) *	1991-06-06	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Agent provocateur du syndrome respiratoire et reproductif du porc, compositions de vaccins et kits de diagnostic
US5846805A (en)	1991-08-26	1998-12-08	Boehringer Ingelheim Animal Health, Inc.	Culture of swine infertility and respiratory syndrome virus in simian cells
AU2508492A (en) †	1991-08-26	1993-03-16	David Allen Benfield	Sirs vaccine and diagnosis method
US6080570A (en) *	1991-08-26	2000-06-27	Boehringer Ingelheim Vetmedica, Inc.	Method of producing a vaccine for Swine Infertility and Respiratory Syndrome
US6982160B2 (en)	1991-08-26	2006-01-03	Boehringer Ingelheim Vetmedica, Inc.	Immunogenic compositions that include SIRS virus
US5695766A (en) *	1992-10-30	1997-12-09	Iowa State University Research Foundation	Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6592873B1 (en)	1992-10-30	2003-07-15	Iowa State University Research Foundation, Inc.	Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6773908B1 (en) *	1992-10-30	2004-08-10	Iowa State University Research Foundation, Inc.	Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6380376B1 (en) *	1992-10-30	2002-04-30	Iowa State University Research Foundation	Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5866401A (en) *	1996-03-01	1999-02-02	Schering Corporation	Porcine reproductive and respiratory syndrome vaccine
JP3135069B2 (ja) *	1996-03-01	2001-02-13	シェーリングコーポレイション	ブタ生殖および呼吸症候群ワクチン
WO2000053787A1 (fr) *	1999-03-08	2000-09-14	Id-Lelystad, Instituut Voor Dierhouderij En Dierg Ezondheid B.V.	Vaccins contre le virus du syndrome dysgenesique respiratoire porcin (srdp)
US20040224327A1 (en) *	1996-10-30	2004-11-11	Meulenberg Johanna Jacoba Maria	Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0839912A1 (fr) *	1996-10-30	1998-05-06	Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo)	Clones infectieux de virus à ARN, vaccins et essais diagnostiques
FR2771375A1 (fr)	1997-11-25	1999-05-28	Saint Gobain Isover	Procede et dispositif de conditionnement de materiaux compressibles
US7132106B2 (en) *	1998-12-22	2006-11-07	Pfizer Inc.	Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7618797B2 (en)	1998-12-22	2009-11-17	Pfizer Inc	Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
NZ501264A (en)	1998-12-22	2001-09-28	Pfizer Prod Inc	Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS
US7691389B2 (en) *	1998-12-22	2010-04-06	Pfizer Inc	Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
EP1183332B1 (fr) *	1999-04-22	2010-07-14	United States Department Of Agriculture	Vaccin contre le syndrome dysgenesique respiratoire porcin base sur l'isolat ja-142
US20020012670A1 (en) *	2000-01-26	2002-01-31	Knut Elbers	Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV)
US7388087B2 (en) *	2000-11-09	2008-06-17	The Board Of Trustees Of The University Of Illinois	Enhancement of immune response to vaccine by interferon alpha
US6841364B2 (en) *	2002-01-22	2005-01-11	Protatek International, Inc.	Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
RU2007101725A (ru) *	2004-06-18	2008-07-27	Риджентс Оф Дзе Юниверсити Оф Миннесота (Us)	Идентификация инфицированных вирусом и вакцинированных вирусом организмов
US7632636B2 (en) *	2004-09-21	2009-12-15	Boehringer Ingelheim Vetmedica, Inc.	Porcine reproductive and respiratory syndrome isolates and methods of use
UA95602C2 (ru)	2004-12-30	2011-08-25	Берингер Ингельхейм Ветмедика, Инк.	Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) *	2004-12-30	2010-11-16	Boehringer Ingelheim Vetmedica, Inc.	Methods of overexpression and recovery of porcine circovirus type 2 ORF2
ATE462445T1 (de)	2005-01-13	2010-04-15	Boehringer Ingelheim Vetmed	Prrs-impfstoffe
US8834891B2 (en)	2005-03-14	2014-09-16	Boehringer Ingelheim Vetmedica, Inc.	Immunogenic compositions comprising Lawsonia intracellularis
AU2006262150B2 (en)	2005-06-24	2011-07-21	Regents Of The University Of Minnesota	PRRS viruses, infectious clones, mutants thereof, and methods of use
ES2814473T3 (es)	2005-12-29	2021-03-29	Boehringer Ingelheim Animal Health Usa Inc	Composiciones inmunogénicas de PCV2 multivalentes y métodos para producir dichas composiciones
PL2371383T3 (pl)	2005-12-29	2016-01-29	Boehringer Ingelheim Vetmedica Inc	Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
US20100129397A1 (en)	2006-12-11	2010-05-27	Boehringer Ingelheim Vetmedica, Inc.	Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
DK2094872T4 (da)	2006-12-15	2020-05-18	Boehringer Ingelheim Animal Health Usa Inc	Behandling af anti-PCV2-antistofseropositive svin med PCV2-antigen
EP1941903A1 (fr)	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxie et traitement du PRDC
CN100523177C (zh) *	2007-01-09	2009-08-05	中国农业科学院哈尔滨兽医研究所	猪繁殖与呼吸综合症病毒弱毒疫苗株及其应用
EP2106440B1 (fr)	2007-01-12	2015-09-16	The Board of Trustees of the University of Illinois	Cellules non simiennes permettant de developper le virus du syndrome dysgenesique et respiratoire du porc (prrs)
US8563313B2 (en) *	2007-02-13	2013-10-22	Washington State University Research Foundation	Macrophage cell-lines for propagation of porcine reproductive and respiratory syndrome virus
EP1958644A1 (fr)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prévention et traitement du PCVD subclinique
US7666585B2 (en) *	2007-06-15	2010-02-23	Protatek International, Inc.	Construction of chimera PRRSV, compositions and vaccine preparations
US7829274B2 (en)	2007-09-04	2010-11-09	Boehringer Ingelheim Vetmedica, Inc.	Reduction of concomitant infections in pigs by the use of PCV2 antigen
US20090317423A1 (en)	2008-01-23	2009-12-24	Boehringer Ingelheim Vetmedica, Inc.	Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
CN101612395B (zh) *	2008-06-24	2012-02-08	扬州优邦生物制药有限公司	一种培养敏感细胞生产蓝耳病疫苗的方法
US20100003278A1 (en) *	2008-07-03	2010-01-07	Boehringer Ingelheim Vetmedica, Inc.	Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
JP5619004B2 (ja) *	2008-08-25	2014-11-05	ベーリンガーインゲルハイムフェトメディカインコーポレイテッド	高病原性ブタ繁殖・呼吸障害症候群（ｈｐｐｒｒｓ）のワクチン
JP5306943B2 (ja) *	2009-08-24	2013-10-02	全国農業協同組合連合会	弱毒ウイルスの作出方法
TWI627281B (zh) *	2009-09-02	2018-06-21	百靈佳殷格翰家畜藥品公司	降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
UA108902C2 (uk)	2010-11-10	2015-06-25		Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
MX355058B (es)	2011-02-17	2018-04-04	Boehringer Ingelheim Vetmedica Gmbh	Nueva cepa del prrsv europea.
CN103370077B (zh)	2011-02-17	2016-10-26	贝林格尔.英格海姆维特梅迪卡有限公司	猪繁殖与呼吸综合征病毒的商业化规模生产方法
WO2013017568A1 (fr)	2011-07-29	2013-02-07	Boehringer Ingelheim Vetmedica Gmbh	Clone d'adnc infectieux du virus srrp européen et ses utilisations
US9187731B2 (en)	2011-07-29	2015-11-17	Boehringer Ingelheim Vetmedica Gmbh	PRRS virus inducing type I interferon in susceptible cells
US8906385B2 (en)	2011-12-01	2014-12-09	University Of Maryland, College Park	Interferon-inducing porcine reproductive and respiratory syndrome virus isolate
HK1201197A1 (en)	2012-05-17	2015-08-28	Zoetis Services Llc	Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
MX366051B (es)	2012-12-07	2019-06-26	Univ Illinois	Composiciones del virus del síndrome reproductor y respiratorio de porcino y sus usos.
EP2968513A2 (fr)	2013-03-15	2016-01-20	Boehringer Ingelheim Vetmedica, Inc.	Virus, compositions, vaccin et procédés d'utilisation du syndrome dysgénésique et respiratoire porcin
CN105658660A (zh)	2013-10-02	2016-06-08	勃林格殷格翰动物保健公司	Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
CN105829528B (zh)	2013-12-20	2019-10-22	勃林格殷格翰动物保健有限公司	PRRS病毒变体、欧洲PRRS病毒cDNA克隆及其用途
CN103690633B (zh) *	2013-12-25	2015-10-28	成都乾坤动物药业有限公司	一种含有枇杷叶的治疗畜禽呼吸道疾病综合征的兽用药物组合物
EA036116B1 (ru)	2015-08-31	2020-09-30	Берингер Ингельхайм Ветмедика Гмбх	Пестивирусные вакцины против врожденного тремора
EP3389706A1 (fr)	2015-12-14	2018-10-24	Boehringer Ingelheim Vetmedica, Inc.	Vaccins pour félins à noyaux hybrides
RS64144B1 (sr)	2016-11-03	2023-05-31	Boehringer Ingelheim Vetmedica Gmbh	Vakcina protiv svinjskog parvovirusa i virusa reproduktivnog i respiratornog sindroma svinja i postupci njegove proizvodnje
US11135285B2 (en) *	2016-11-29	2021-10-05	Intervet Inc.	Swine vaccine
BR112019012158A2 (pt)	2016-12-14	2019-11-12	Zoetis Services Llc	vacinação eficaz contra cepas europeias de vírus da síndrome reprodutiva e respiratória suína (prrs) antes do desmame
WO2018189290A1 (fr)	2017-04-13	2018-10-18	Intervet International B.V.	Vaccins contenant des pathogènes porcins destinés à être utilisés en association sans mélange
JP7762565B2 (ja)	2019-04-04	2025-10-30	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	３型ブタサーコウイルス（ｐｃｖ３）ワクチン、ならびにその作製および使用
BR112023001324A2 (pt)	2020-07-24	2023-02-14	Boehringer Ingelheim Animal Health Usa Inc	Combinação de vacina de suíno

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4753884A (en) *	1986-01-28	1988-06-28	Novagene, Inc.	Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
CA2076744C (fr) *	1991-08-26	2000-06-27	Danny W. Chladek	Agent viral associe a la maladie mysterieuse du porc
AU2508492A (en) *	1991-08-26	1993-03-16	David Allen Benfield	Sirs vaccine and diagnosis method
US5695766A (en) *	1992-10-30	1997-12-09	Iowa State University Research Foundation	Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
DE69426228T2 (de) *	1993-02-08	2001-03-01	Bayer Ag	Verfahren zum Vermehren des das Reproduktions- und Atemwegs-Syndrom verursachenden Schweinevirus und dessen Verwendung als Impfstoff.
ES2074950B1 (es) *	1993-09-17	1996-03-16	Iberica Cyanamid	Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.

1995
- 1995-05-15 US US08/440,750 patent/US6042830A/en not_active Expired - Lifetime
1996
- 1996-05-14 JP JP53495496A patent/JP4300252B2/ja not_active Expired - Fee Related
- 1996-05-14 KR KR1019970708184A patent/KR19990014840A/ko not_active Ceased
- 1996-05-14 BR BRPI9608535-5A patent/BR9608535B1/pt not_active IP Right Cessation
- 1996-05-14 CZ CZ0361697A patent/CZ296208B6/cs not_active IP Right Cessation
- 1996-05-14 UA UA97126039A patent/UA39991C2/uk unknown
- 1996-05-14 EP EP19960915746 patent/EP0830142B1/fr not_active Revoked
- 1996-05-14 DK DK96915746T patent/DK0830142T3/da active
- 1996-05-14 CN CN96195440A patent/CN1130227C/zh not_active Expired - Lifetime
- 1996-05-14 PT PT96915746T patent/PT830142E/pt unknown
- 1996-05-14 AT AT96915746T patent/ATE213166T1/de not_active IP Right Cessation
- 1996-05-14 DE DE69619233T patent/DE69619233T2/de not_active Revoked
- 1996-05-14 RU RU97120712A patent/RU2166327C2/ru active
- 1996-05-14 PL PL96323365A patent/PL184973B1/pl unknown
- 1996-05-14 SK SK1539-97A patent/SK283579B6/sk not_active IP Right Cessation
- 1996-05-14 WO PCT/US1996/006800 patent/WO1996036356A1/fr not_active Ceased
- 1996-05-14 HU HU9802493A patent/HU223763B1/hu active IP Right Grant
- 1996-05-14 ES ES96915746T patent/ES2170234T3/es not_active Expired - Lifetime
- 1996-05-14 AU AU57443/96A patent/AU717395B2/en not_active Expired
- 1996-05-14 CA CA 2221242 patent/CA2221242C/fr not_active Expired - Lifetime
- 1996-08-15 US US08/698,240 patent/US5989563A/en not_active Expired - Lifetime
1997
- 1997-11-14 MX MX9708804A patent/MX9708804A/es unknown

Also Published As

Publication number	Publication date
KR19990014840A (ko)	1999-02-25
CN1190349A (zh)	1998-08-12
CZ296208B6 (cs)	2006-02-15
PL323365A1 (en)	1998-03-30
HUP9802493A2 (hu)	1999-02-01
US5989563A (en)	1999-11-23
AU717395B2 (en)	2000-03-23
RU2166327C2 (ru)	2001-05-10
HUP9802493A3 (en)	2001-10-29
EP0830142A4 (fr)	1998-09-02
DK0830142T3 (da)	2002-04-22
ATE213166T1 (de)	2002-02-15
HU223763B1 (hu)	2005-01-28
MX9708804A (es)	1998-10-31
SK153997A3 (en)	1998-07-08
JP4300252B2 (ja)	2009-07-22
WO1996036356A1 (fr)	1996-11-21
CA2221242C (fr)	2002-10-29
CN1130227C (zh)	2003-12-10
HK1016872A1 (en)	1999-11-12
UA39991C2 (uk)	2001-07-16
AU5744396A (en)	1996-11-29
SK283579B6 (sk)	2003-09-11
PT830142E (pt)	2002-07-31
CA2221242A1 (fr)	1996-11-21
DE69619233D1 (en)	2002-03-21
EP0830142B1 (fr)	2002-02-13
CZ361697A3 (cs)	1998-06-17
JPH11505248A (ja)	1999-05-18
BR9608535A (pt)	1999-06-15
ES2170234T3 (es)	2002-08-01
EP0830142A1 (fr)	1998-03-25
US6042830A (en)	2000-03-28
BR9608535B1 (pt)	2012-02-22
PL184973B1 (pl)	2003-01-31

Publication	Publication Date	Title
DE69619233T2 (de)	2002-08-22	Prrs-(porcine reproductive and respiratory syndrome)-virusvakzin
EP0529584B1 (fr)	1996-07-10	Agent viral associé avec la Mystery Swine Disease
DE69426228T2 (de)	2001-03-01	Verfahren zum Vermehren des das Reproduktions- und Atemwegs-Syndrom verursachenden Schweinevirus und dessen Verwendung als Impfstoff.
DE69704011T2 (de)	2001-06-07	Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Sweins (PRRSV)
DE69620402T2 (de)	2002-11-07	Prrs-virus-lebendimpfstoffe mit geringer pathogenitaet und verfahren zu deren herstellung
DE69522984T2 (de)	2002-04-25	Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Schweins
DE69214657T3 (de)	2001-05-03	Vakzine gegen und diagnosemethode für das schweine-unfruchtbarkeits- und atmungs-syndrom (suas)
DE4432338C2 (de)	1997-10-30	Impfstoff zur Verhinderung des reproduktiven und respiratorischen Syndroms bei Schweinen
DE69334141T2 (de)	2008-01-24	Schweinevirus, Erreger der sich vermehrenden Erkrankung der Atemwege, Impstoffe und seine virale DNA
DE69936977T2 (de)	2008-05-29	Durch polynukleinsäuren vom reproduktiven und respiratorischen syndromvirus des schweines kodierte proteine
Andries et al.	1978	Effect of experimental infection with pseudorabies (Aujeszky's disease) virus on pigs with maternal immunity from vaccinated sows
DE69426051T2 (de)	2001-05-10	Impfstoff für Geflügel
DE19517773A1 (de)	1995-11-16	Rekombinante PRRSV-Proteine, Diagnostik-Kits und solche rekombinanten PRRSV-Proteine enthaltenden Vakzinen
DE3882599T2 (de)	1994-02-10	Hundecoronavirus-Impfstoff.
RU2187333C2 (ru)	2002-08-20	Вакцина для защиты свиней от репродуктивного и респираторного синдрома и способ защиты свиней
US5213795A (en)	1993-05-25	Encephalomyocarditis virus vaccine
HK1016872B (en)	2004-08-27	Viral agent associated with mystery swine disease
DE2544510A1 (de)	1977-04-14	Virales rhinotracheitisvakzin fuer das katzengeschlecht und verfahren zu dessen herstellung
MXPA97010149A (en)	1998-11-09	Live pathogenicity live virus vaccines and methods of preparation of mis
MXPA98007083A (en)	1999-02-01	Vaccine against the reproductive and respiratory syndrome porc
DE1767882A1 (de)	1971-09-30	Vakzin und Verfahren zur Verhinderung der uebertragbaren Gastroenteritis bei Schweinen
HK1005014B (en)	1998-12-18	Sirs vaccine and diagnosis method

Legal Events

Date	Code	Title	Description
2002-07-04	8327	Change in the person/name/address of the patent owner	Owner name: BOEHRINGER INGELHEIM VETMEDICA, INC., ST. JOSEPH,
2003-02-13	8363	Opposition against the patent
2008-06-19	8331	Complete revocation